Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Denali Therapeutics Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Denali Therapeutics received notice from Takeda Pharmaceutical terminating their January 2018 collaboration agreement on DNL593 due to strategic considerations, with all program rights reverting to Denali after a 60-day notice period. This represents a significant shift in Denali's pipeline strategy and removes a major partnership, potentially impacting near-term revenue and development timelines.
Key Takeaways
Takeda terminated the collaboration agreement effective 60 days from April 3, 2026, citing strategic reasons unrelated to safety or efficacy concerns
All rights to the DNL593 program revert to Denali, giving the company full control but also full responsibility for future development
2 more takeaways
Related Filings (4)
4 more filings from Denali Therapeutics Inc. in the last 90 days